Quantum-Si (QSI) Earnings Date & Reports

Key Takeaways

• Third quarter 2026 revenue fell to $212,000, down from $552,000 a year earlier, missing consensus estimates of roughly $280,000 as the Platinum-to-Proteus transition suppressed near-term sales.
• GAAP (Generally Accepted Accounting Principles) net loss narrowed to $22.3 million, or $0.10 per share, beating analyst estimates of about a $0.12 loss per share.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) improved to negative $17.0 million from negative $20.1 million a year ago, aided by the August restructuring.
• Management reiterated 2026 revenue guidance of approximately $1.0 million while lowering adjusted operating expense and total cash usage guidance to $87 million or less each.
• Cash, cash equivalents, and marketable securities totaled $149.4 million, extending the funding runway into the fourth quarter of 2028, with the Proteus launch still targeted for the second quarter of 2027.
• For more on Quantum-Si's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages covering each area.
• To discover trade ideas and market opportunities powered by artificial intelligence, explore Trending AI Robots.

Earnings Context and Why It Matters

Quantum-Si is a proteomics technology company developing single-molecule protein sequencing platforms, and its quarterly results are closely watched less for near-term revenue than for progress toward its next-generation Proteus instrument. The company is currently navigating a deliberate transition away from its earlier Platinum platform, a period in which management has said sales will reflect lower instrument demand and customer planning for the new system. With revenue still small and operating losses ongoing, investors focus primarily on cost discipline, cash runway, and execution milestones. This report matters because it signals whether Quantum-Si can preserve enough capital to reach a commercially meaningful launch while keeping Proteus on its stated timeline.

Reported Results

For the third quarter of 2026, Quantum-Si reported total revenue of $212,000, down from $552,000 in the prior-year quarter and below the consensus estimate of roughly $280,000. The decline reflects limited near-term capital purchasing for Platinum, ongoing consumable usage from the installed base, and customer awareness of the anticipated Proteus launch. Gross profit was $74,000, producing a gross margin of 35%, consistent with the prior-year period.

The company posted a GAAP net loss of $22.3 million, or $0.10 per share, an improvement from a net loss of $35.7 million, or $0.17 per share, a year earlier and better than the estimated loss of about $0.12 per share. Total operating expenses fell to $23.9 million from $40.0 million, which had included lease termination and legal settlement charges. Adjusted total operating expenses were $18.2 million versus $21.4 million a year ago, while adjusted EBITDA improved to negative $17.0 million from negative $20.1 million.

For full-year 2026, management reiterated revenue guidance of approximately $1.0 million and lowered its outlook for adjusted total operating expenses and total cash usage to $87 million or less each, down from $98 million and $93 million, respectively. The company ended the quarter with $149.4 million in cash, cash equivalents, and marketable securities.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable criteria such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, giving investors a faster way to narrow the investable universe. For those tracking pre-revenue and early-stage names like Quantum-Si, it can help identify comparable opportunities across the broader market.

Market Reaction and Investor Sentiment

Investor sentiment around Quantum-Si remains focused on the Proteus launch rather than the company's modest quarterly revenue. The narrower-than-expected loss and improved cost discipline were viewed favorably, but the revenue shortfall reinforced that 2026 and the first half of 2027 are expected to be transition quarters with limited sales. The stock has been volatile around recent reports, with prior earnings events generating notable post-announcement moves as traders reposition on launch-timeline updates. Key risks heading forward include further delays to Proteus commercialization, supply-chain constraints on long-lead components, and any erosion of the cash runway before the new platform reaches the market.

Forward Outlook and Key Factors to Monitor

The most important catalyst remains the Proteus commercial launch, which management continues to target for the second quarter of 2027. The company said it has substantially addressed instrument variability issues identified earlier in development and has completed design activities for an additional instrument cycle. Investors should watch for confirmation of the year-end 2026 demonstration of detection of all 20 amino acids, a technical milestone tied to the platform's core value proposition.

Supply-chain execution is another key area to monitor. Management noted that AI-driven demand has extended lead times for certain components, prompting earlier orders, supplier volume commitments, and safety-stock buildup for critical parts. Any further supply disruptions could pressure the launch timeline.

Finally, cost control and cash usage remain central. The August restructuring, which reduced headcount by roughly 20%, is expected to deliver about $12 million in annual operating expense savings. With the company guiding to total cash usage of $87 million or less in 2026 and a runway into the fourth quarter of 2028, investors will track whether spending stays within plan while preserving the manufacturing and commercial readiness needed to bring Proteus to market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations